Price Alert

Y-mAbs Therapeutics Inc. (YMAB)

NASDAQ: YMAB · Real-Time Price · USD

8.52

0.01 (0.12%)

At close: Aug 15, 2025, 2:11 PM

Y-mAbs Therapeutics Statistics

Share Statistics

Y-mAbs Therapeutics has 45.3M shares outstanding. The number of shares has increased by 1.63% in one year.

Shares Outstanding	45.3M
Shares Change (YoY)	1.63%
Shares Change (QoQ)	0.17%
Owned by Institutions (%)	63.84%
Shares Floating	33.9M
Failed to Deliver (FTD) Shares	1,999
FTD / Avg. Volume	0.32%

Short Selling Information

The latest short interest is 2.49M, so 5.49% of the outstanding shares have been sold short.

Short Interest	2.49M
Short % of Shares Out	5.49%
Short % of Float	6.51%
Short Ratio (days to cover)	19.88

Valuation Ratios

The PE ratio is -11.7 and the forward PE ratio is -8.11. Y-mAbs Therapeutics's PEG ratio is -0.32.

PE Ratio	-11.7
Forward PE	-8.11
PS Ratio	3.96
Forward PS	4.1
PB Ratio	3.77
P/FCF Ratio	-22.09
PEG Ratio	-0.32

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Y-mAbs Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.01.

Current Ratio	4.16
Quick Ratio	3.85
Debt / Equity	0.01
Debt / EBITDA	-0.03
Debt / FCF	-0.05
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$843.13K
Profits Per Employee	$-285.25K
Employee Count	104
Asset Turnover	0.73
Inventory Turnover	2.11

Taxes

Income Tax	-146K
Effective Tax Rate	0.49%

Stock Price Statistics

The stock price has increased by -14.37% in the last 52 weeks. The beta is 0.56, so Y-mAbs Therapeutics's price volatility has been higher than the market average.

Beta	0.56
52-Week Price Change	-14.37%
50-Day Moving Average	4.95
200-Day Moving Average	6.75
Relative Strength Index (RSI)	81.64
Average Volume (20 Days)	619,267

Income Statement

In the last 12 months, Y-mAbs Therapeutics had revenue of 87.69M and earned -29.67M in profits. Earnings per share was -0.67.

Revenue	87.69M
Gross Profit	72.43M
Operating Income	-31.2M
Net Income	-29.67M
EBITDA	-30.67M
EBIT	-31.2M
Earnings Per Share (EPS)	-0.67

Full Income Statement

Balance Sheet

The company has 67.23M in cash and 820K in debt, giving a net cash position of 66.41M.

Cash & Cash Equivalents	67.23M
Total Debt	820K
Net Cash	66.41M
Retained Earnings	-487.14M
Total Assets	112.61M
Working Capital	71.49M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.71M and capital expenditures 0, giving a free cash flow of -15.71M.

Operating Cash Flow	-15.71M
Capital Expenditures	n/a
Free Cash Flow	-15.71M
FCF Per Share	-0.35

Full Cash Flow Statement

Margins

Gross margin is 82.61%, with operating and profit margins of -35.58% and -33.83%.

Gross Margin	82.61%
Operating Margin	-35.58%
Pretax Margin	-34%
Profit Margin	-33.83%
EBITDA Margin	-34.97%
EBIT Margin	-35.58%
FCF Margin	-17.92%

Dividends & Yields

YMAB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for YMAB is $14.5, which is 70.2% higher than the current price. The consensus rating is "Buy".

Price Target	$14.5
Price Target Difference	70.2%
Analyst Consensus	Buy
Analyst Count	11

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	4.51
Piotroski F-Score	2